Literature DB >> 18400858

Ninety-nine is not enough: molecular characterization of inhibitor-resistant human immunodeficiency virus type 1 protease mutants with insertions in the flap region.

Milan Kozísek1, Klára Grantz Sasková, Pavlína Rezácová, Jirí Brynda, Noortje M van Maarseveen, Dorien De Jong, Charles A Boucher, Ron M Kagan, Monique Nijhuis, Jan Konvalinka.   

Abstract

While the selection of amino acid insertions in human immunodeficiency virus (HIV) reverse transcriptase (RT) is a known mechanism of resistance against RT inhibitors, very few reports on the selection of insertions in the protease (PR) coding region have been published. It is still unclear whether these insertions impact protease inhibitor (PI) resistance and/or viral replication capacity. We show that the prevalence of insertions, especially between amino acids 30 to 41 of HIV type 1 (HIV-1) PR, has increased in recent years. We identified amino acid insertions at positions 33 and 35 of the PR of HIV-1-infected patients who had undergone prolonged treatment with PIs, and we characterized the contribution of these insertions to viral resistance. We prepared the corresponding mutated, recombinant PR variants with or without insertions at positions 33 and 35 and characterized them in terms of enzyme kinetics and crystal structures. We also engineered the corresponding recombinant viruses and analyzed the PR susceptibility and replication capacity by recombinant virus assay. Both in vitro methods confirmed that the amino acid insertions at positions 33 and 35 contribute to the viral resistance to most of the tested PIs. The structural analysis revealed local structural rearrangements in the flap region and in the substrate binding pockets. The enlargement of the PR substrate binding site together with impaired flap dynamics could account for the weaker inhibitor binding by the insertion mutants. Amino acid insertions in the vicinity of the binding cleft therefore represent a novel mechanism of HIV resistance development.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18400858      PMCID: PMC2395164          DOI: 10.1128/JVI.02325-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Inhibitor binding at the protein interface in crystals of a HIV-1 protease complex.

Authors:  Jirí Brynda; Pavlína Rezácová; Milan Fábry; Magdalena Horejsí; Renata Stouracová; Milan Soucek; Martin Hradílek; Jan Konvalinka; Juraj Sedlácek
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-10-20

2.  A novel real-time PCR assay to determine relative replication capacity for HIV-1 protease variants and/or reverse transcriptase variants.

Authors:  N M van Maarseveen; M C D G Huigen; D de Jong; A M Smits; C A B Boucher; M Nijhuis
Journal:  J Virol Methods       Date:  2005-12-20       Impact factor: 2.014

3.  Rapid and simple method for purification of nucleic acids.

Authors:  R Boom; C J Sol; M M Salimans; C L Jansen; P M Wertheim-van Dillen; J van der Noordaa
Journal:  J Clin Microbiol       Date:  1990-03       Impact factor: 5.948

4.  Amino acid insertions at position 35 of HIV-1 protease interfere with virus replication without modifying antiviral drug susceptibility.

Authors:  Stefania Paolucci; Fausto Baldanti; Luca Dossena; Giuseppe Gerna
Journal:  Antiviral Res       Date:  2006-01-20       Impact factor: 5.970

5.  An increase in viral replicative capacity drives the evolution of protease inhibitor-resistant human immunodeficiency virus type 1 in the absence of drugs.

Authors:  Noortje M van Maarseveen; Dorien de Jong; Charles A B Boucher; Monique Nijhuis
Journal:  J Acquir Immune Defic Syndr       Date:  2006-06       Impact factor: 3.731

6.  Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure.

Authors:  S V Gulnik; L I Suvorov; B Liu; B Yu; B Anderson; H Mitsuya; J W Erickson
Journal:  Biochemistry       Date:  1995-07-25       Impact factor: 3.162

7.  Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments.

Authors:  Thomas D Wu; Celia A Schiffer; Matthew J Gonzales; Jonathan Taylor; Rami Kantor; Sunwen Chou; Dennis Israelski; Andrew R Zolopa; W Jeffrey Fessel; Robert W Shafer
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

8.  Functional correlates of insertion mutations in the protease gene of human immunodeficiency virus type 1 isolates from patients.

Authors:  E Y Kim; M A Winters; R M Kagan; T C Merigan
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

9.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors.

Authors:  J H Condra; W A Schleif; O M Blahy; L J Gabryelski; D J Graham; J C Quintero; A Rhodes; H L Robbins; E Roth; M Shivaprakash
Journal:  Nature       Date:  1995-04-06       Impact factor: 49.962

Review 10.  Anti-HIV drugs.

Authors:  E De Clercq
Journal:  Verh K Acad Geneeskd Belg       Date:  2007
View more
  18 in total

1.  Computational analysis of HIV-1 protease protein binding pockets.

Authors:  Gene M Ko; A Srinivas Reddy; Sunil Kumar; Barbara A Bailey; Rajni Garg
Journal:  J Chem Inf Model       Date:  2010-10-25       Impact factor: 4.956

2.  HIV-1 protease with 20 mutations exhibits extreme resistance to clinical inhibitors through coordinated structural rearrangements.

Authors:  Johnson Agniswamy; Chen-Hsiang Shen; Annie Aniana; Jane M Sayer; John M Louis; Irene T Weber
Journal:  Biochemistry       Date:  2012-03-20       Impact factor: 3.162

3.  Mutations in HIV-1 gag and pol compensate for the loss of viral fitness caused by a highly mutated protease.

Authors:  Milan Kozísek; Sandra Henke; Klára Grantz Sasková; Graeme Brendon Jacobs; Anita Schuch; Bernd Buchholz; Viktor Müller; Hans-Georg Kräusslich; Pavlína Rezácová; Jan Konvalinka; Jochen Bodem
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

4.  Novel codon insert in HIV type 1 clade B reverse transcriptase associated with low-level viremia during antiretroviral therapy.

Authors:  Antoine Chaillon; Sara Gianella; Homero Vazquez; Caroline Ignacio; Adam C Zweig; Douglas D Richman; Davey M Smith
Journal:  AIDS Res Hum Retroviruses       Date:  2013-10-05       Impact factor: 2.205

Review 5.  Highly resistant HIV-1 proteases and strategies for their inhibition.

Authors:  Irene T Weber; Daniel W Kneller; Andres Wong-Sam
Journal:  Future Med Chem       Date:  2015       Impact factor: 3.808

6.  Computational mutation scanning and drug resistance mechanisms of HIV-1 protease inhibitors.

Authors:  Ge-Fei Hao; Guang-Fu Yang; Chang-Guo Zhan
Journal:  J Phys Chem B       Date:  2010-07-29       Impact factor: 2.991

7.  Structural and biochemical characterization of a novel aminopeptidase from human intestine.

Authors:  Jan Tykvart; Cyril Bařinka; Michal Svoboda; Václav Navrátil; Radko Souček; Martin Hubálek; Martin Hradilek; Pavel Šácha; Jacek Lubkowski; Jan Konvalinka
Journal:  J Biol Chem       Date:  2015-03-09       Impact factor: 5.157

8.  Molecular characterization of clinical isolates of human immunodeficiency virus resistant to the protease inhibitor darunavir.

Authors:  Klára Grantz Sasková; Milan Kozísek; Pavlína Rezácová; Jirí Brynda; Tatyana Yashina; Ron M Kagan; Jan Konvalinka
Journal:  J Virol       Date:  2009-06-17       Impact factor: 5.103

9.  A novel codon insert in protease of clade B HIV type 1.

Authors:  Parris S Jordan; Art Poon; Joseph Eron; Kathleen Squires; Caroline Ignacio; Douglas D Richman; Davey M Smith
Journal:  AIDS Res Hum Retroviruses       Date:  2009-05       Impact factor: 2.205

10.  GS-8374, a prototype phosphonate-containing inhibitor of HIV-1 protease, effectively inhibits protease mutants with amino acid insertions.

Authors:  Klára Grantz Šašková; Milan Kozíšek; Kirsten Stray; Dorien de Jong; Pavlína Rezáová; Jirí Brynda; Noortje M van Maarseveen; Monique Nijhuis; Tomáš Cihlár; Jan Konvalinka
Journal:  J Virol       Date:  2013-12-26       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.